SCHEMBL5652549

SCHEMBL5652549

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cc(Br)c(C)c(C)c3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.44
HDAC4 P56524 3/20 0.44
HDAC2 Q92769 3/20 0.44
HDAC8 Q9BY41 3/20 0.44
MAPT P10636 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC9 Q9UKV0 2/20 0.43
HDAC5 Q9UQL6 2/20 0.43
HTT P42858 2/20 0.42
GAA P10253 2/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ACP1 P24666 1/20 0.42
IGF1R P08069 1/20 0.42
TSHR P16473 3/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649820 0.89 GAA (0.45) HDAC6HDAC4HDAC2HDAC8MAPT
SCHEMBL5648651 0.88 GAA (0.44) HDAC6HDAC4HDAC2HDAC8MAPT
SCHEMBL5652790 0.87 GAA (0.43) HDAC6HDAC4HDAC2HDAC8MAPT
SCHEMBL5651885 0.86 FLT3 (0.45) HDAC6CDK2IKBKEAURKBTBK1
SCHEMBL5653197 0.85 PRMT5 (0.48) MAPTHTTGAATP53SMN1; SMN2
SCHEMBL5652552 0.85 HDAC6 (0.44) HDAC6HDAC4HDAC2HDAC8MAPT
SCHEMBL5652434 0.84 PRMT5 (0.41) HDAC6MAPTHTTGAATP53
SCHEMBL5647630 0.83 ACKR3 (0.46) MAPTHTTTP53SMN1; SMN2KMT2A
SCHEMBL5649064 0.82 HDAC6 (0.46) HDAC6HDAC4HDAC2HDAC8MAPT
SCHEMBL5647859 0.80 HDAC6 (0.46) HDAC6HDAC4HDAC2HDAC8MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 HDAC6 537/4885HDAC4 249/4885HDAC2 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.